教育
Education
研究活動
研究概要
テーマ：がん化学療法、早期・後期開発、大腸癌、胃癌、トランスレーショナル・リサーチ、個別化医療、、呼吸器、化学療法
臨床・分子遺伝学的および臓器横断的な立場から、がんに関連した基礎・臨床研究を遂行しています。
研究活動
| ・ | 新規抗がん剤開発、特に早期開発およびそのトランスレーショナル・リサーチ |
| ・ | 消化器がんに対する後期開発、臨床試験 |
| ・ | 薬物代謝酵素の遺伝子多型、臓器の機能低下等による抗がん剤の薬物動態への影響および有害反応、効果との相関解析 |
| ・ | ゲノム医療実践のためのシークエンス技術開発 |
| ・ | メタボローム、マイクロRNA等解析による早期診断マーカーの開発 |
| ・ | 免疫チェックポイント阻害剤の効果予測、予後予測に関連する免疫マーカー探索 |
| ・ | 免疫チェックポイント阻害剤治療におけるMRIを用いた新規評価法の開発 |
| ・ | 免疫チェックポイント阻害剤治療における末梢血免疫プロファイル解析 |
| ・ | 進行非小細胞肺癌に対する新たな全身化学療法の開発を目的とした多施設共同臨床研究の立案遂行・データ解析 |
| ・ | 抗癌剤に伴う副作用に対する新たな支持療法の開発を目的とした多施設共同臨床研究の立案・遂行・データ解析 |
| ・ | 抗癌剤に伴う薬剤性肺障害に関する臨床的研究 |
| ・ | 間質性肺炎合併肺癌に関する臨床的研究 |
| ・ | 肺癌における血管新生阻害剤が既存の肺血管に及ぼす影響に関する研究 |
| ・ | 脂質解析に基づく抗がん剤耐性機序の解明 |
| ・ | 質量顕微鏡法による消化器悪性腫瘍の解析 |
研究業績（2001年以降 代表論文）
教授 山田 康秀
| 2020 - 2021 | |
| 1. | Relationship between cervical esophageal squamous cell carcinoma and human papilloma virus infection and gene mutations. Fukahori M, Kato K, Taniguchi H, Ohtomo R, Takahashi N, Shoji H, Iwasa S, Honma Y, Takashima A, Hamaguchi T, Yamada Y, Shimada Y, Ito Y, Itami J, Hokamura N, Igaki H, Tachimori Y, Miwa K, Torimura T, Boku N. Mol Clin Oncol. 2021 |
| 2. | Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trial. Yamada Y, Muro K, Takahashi K, Baba H, Komatsu Y, Satoh T, Goto M, Mishima H, Watanabe M, Sakata Y, Morita S, Shimada Y, Takenaka N, Hirooka T, Sugihara K. Glob Health Med. 2020 |
| 3. | Present status and perspective of chemotherapy for patients with unresectable advanced or metastatic gastric cancer in Japan. Yamada Y. Glob Health Med. 2020 |
| 4. | Impact of CYP2D6 activity and cachexia progression on enantiomeric alteration of plasma tramadol and its demethylated metabolites and their relationships with central nervous system symptoms in head and neck cancer patients. Suzuki K, Naito T, Tanaka H, Shibata K, Yamada Y, Itoh K, Kawakami J. Basic Clin Pharmacol Toxicol. 2021 |
| 5. | Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503). Iwasa S, Okita N, Kuchiba A, Ogawa G, Kawasaki M, Nakamura K, Shoji H, Honma Y, Takashima A, Kato K, Hamaguchi T, Boku N, Yamada Y. ESMO Open. 2020 |
| 6. | A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer. Matsuyama T, Kandimalla R, Ishikawa T, Takahashi N, Yamada Y, Yasuno M, Kinugasa Y, Hansen TF, Fakih M, Uetake H, Győrffy B, Goel A. Int J Cancer. 2020 |
| 7. | Randomized, Double-Blind, Placebo-Controlled Phase Ⅱ Study on the Efficacy and Safety of Vitamin K1 Ointment for Cetuximab or Panitumumab-Induced Acneiform Eruptions-VIKTORIA Study. Hashimoto H, Iwasa S, Yanai-Takahashi T, Honma Y, Kato K, Hamaguchi T, Yamada Y, Shimada Y, Yamazaki N, Kato Y. Gan To Kagaku Ryoho. 2020 J |
| 8. | Promotion of the Warburg effect is associated with poor benefit from adjuvant chemotherapy in colorectal cancer. Kitazawa M, Hatta T, Sasaki Y, Fukui K, Ogawa K, Fukuda E, Goshima N, Okita N, Yamada Y, Nakagama H, Natsume T, Horimoto K. Cancer Sci. 2020 |
| 9. | A Reversed-Phase Mode LC-MS/MS Method Using a Polysaccharide Chiral Selector for Simultaneous Quantitation of Each Enantiomer of Tramadol and its Metabolites in Human Plasma and Evaluation of CYP-Mediated Stereoselective Demethylation. Suzuki K, Naito T, Tanaka H, Yamada Y, Itoh K, Kawakami J. Ther Drug Monit. 2020 |
| 2019 - 2017 | |
| 10. | Sex differences in safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer. Yamada Y, Koizumi W, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Hyodo I. Cancer Sci. 2019 |
| 11. | Gastric mucosal injury and hemorrhage after definitive chemoradiotherapy for locally advanced esophageal cancer. Monma S, Kato K, Shouji H, Okita N, Takashima A, Honma Y, Iwasa S, Hamaguchi T, Yamada Y, Shimada Y, Boku N, Nagashima K, Ito Y, Itami J. Esophagus 2019 |
| 12. | Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Yamada Y, Boku N, Mizusawa J, Iwasa S, Kadowaki S, Nakayama N, Azuma M, Sakamoto T, Shitara K, Tamura T, Chin K, Hata H, Nakamori M, Hara H, Yasui H, Katayama H, Fukuda H, Yoshikawa T, Sasako M, Terashima M. Lancet Gastroenterol Hepatol 2019 |
| 13. | Transcriptomic expression profiling identifies ITGBL1, an epithelial to mesenchymal transition (EMT)-associated gene, is a promising recurrence prediction biomarker in colorectal cancer. Matsuyama T, Ishikawa T, Takahashi N, Yamada Y, Yasuno M, Kawano T, Uetake H, Goel A. Mol Cancer 2019 |
| 14. | Phase I study of alpelisib (BYL719), an α-specific PI3K inhibitor, in Japanese patients with advanced solid tumors. Ando Y, Iwasa S, Takahashi S, Saka H, Kakizume T, Natsume K, Suenaga N, Quadt C, Yamada Y. Cancer Sci , 2018 |
| 15. | LC-MS/MS method for denosumab quantitation in human serum with rapid protein digestion using immobilized trypsin. Shida H, Naito T, Shibata K, Yamada Y, Kawakami J. Bioanalysis , 2018 |
| 16. | Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients. Tanaka H, Naito T, Sato H, Hiraide T, Yamada Y, Kawakami J. Eur J Clin Pharmacol , 2018 |
| 17. | A comprehensive methylation signature identifies lymph node metastasis in esophageal squamous cell carcinoma. Roy R, Kandimalla R, Sonohara F, Koike M, Kodera Y, Takahashi N, Yamada Y, Goel A. Int J Cancer , 2019 |
| 18. | Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Xu RH, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS, Kim TW. Lancet Oncol , 2018 |
| 19. | AZIN1 RNA editing confers cancer stemness and enhances oncogenic potential in colorectal cancer. Shigeyasu K, Okugawa Y, Toden S, Miyoshi J, Toiyama Y, Nagasaka T, Takahashi N, Kusunoki M, Takayama T, Yamada Y, Fujiwara T, Chen L, Goel A. JCI Insight , 2018 |
| 20. | Imaging peritoneal metastasis of gastric cancer with 18F-fluorothymidine positron emission tomography/computed tomography: a proof-of-concept study. Honma Y, Terauchi T, Tateishi U, Kano D, Nagashima K, Shoji H, Iwasa S, Takashima A, Kato K, Hamaguchi T, Boku N, Shimada Y, Yamada Y. Br J Radiol , 2018 |
| 21. | Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer. Okita A, Takahashi S, Ouchi K, Inoue M, Watanabe M, Endo M, Honda H, Yamada Y, Ishioka C. Oncotarget , 2018 |
| 22. | S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase 3, non-inferiority trial. Yamada Y, Denda T, Gamoh M, Iwanaga I, Yuki S, Shimodaira H, Nakamura M, Yamaguchi T, Ohori H, Kobayashi K, Tsuda M, Kobayashi Y, Miyamoto Y, Kotake M, Shimada K, Sato A, Morita S, Takahashi S, Komatsu Y, Ishioka C. Ann Oncol , 2018 |
| 23. | Genome-wide discovery and identification of a novel miRNA signature for recurrence prediction in stage II and III colorectal cancer. Kandimalla R, Gao F, Matsuyama T, Ishikawa T, Uetake H, Takahashi N, Yamada Y, Becerra CR, Kopetz S, Wang X, Goel A. Clin Cancer Res 2018 |
| 24. | A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma. Hiramoto S, Kato K, Shoji H, Okita N, Takashima A, Honma Y, Iwasa S, Hamaguchi T, Yamada Y, Shimada Y, Boku N. Int J Clin Oncol , 2018 |
| 25. | Genome-wide Discovery of a Novel Gene-expression Signature for the Identification of Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma. Sonohara F, Gao F, Iwata N, Kanda M, Koike M, Takahashi N, Yamada Y, Kodera Y, Wang X, Goel A. Ann Surg, 2017 |
| 26. | A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15-minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin- and Irinotecan-refractory, KRAS Wild-type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial). Akiyoshi K, Hamaguchi T, Yoshimura K, Takahashi N, Honma Y, Iwasa S, Takashima A, Kato K, Yamada Y, Onodera H, Takeshita S, Yasui H, Sakai G, Akatsuka S, Ogawa K, Horita Y, Nagai Y, Shimada Y. Clin Colorectal Cancer , 2018 |
| 27. | Patterns of Relapse after Definitive Chemoradiotherapy in Stage II/III (Non-T4) Esophageal Squamous Cell Carcinoma. Sudo K, Kato K, Kuwabara H, Sasaki Y, Takahashi N, Shoji H, Iwasa S, Honma Y, Okita NT, Takashima A, Hamaguchi T, Yamada Y, Ito Y, Itami J, Fukuda T, Tobinai K, Boku N. Oncology , 2018 |
| 28. | Phase I study of single-agent ribociclib in Japanese patients with advanced solid tumors. Doi T, Hewes B, Kakizume T, Tajima T, Ishikawa N, Yamada Y. Cancer Sci , 2018 |
| 29. | Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm. Sawaki A, Yamada Y, Yamaguchi K, Nishina T, Doi T, Satoh T, Chin K, Boku N, Omuro Y, Komatsu Y, Hamamoto Y, Koizumi W, Saji S, Shah MA, Van Cutsem E, Kang YK, Iwasaki J, Kuriki H, Ohtsuka W, Ohtsu A. Gastric Cancer , 2018 |
| 30. | microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer. Takahashi H, Takahashi M, Ohnuma S, Unno M, Yoshino Y, Ouchi K, Takahashi S, Yamada Y, Shimodaira H, Ishioka C. BMC Cancer , 2017 |
| 31. | S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study. Baba H, Yamada Y, Takahari D, Matsumoto H, Yoshida K, Nakamura M, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, Sasaki Y, Satoh T, Takahashi K, Mishima H, Muro K, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K. ESMO Open, 2017 |
|
2017 - 2015 |
|
| 32. | Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma. Delord JP, Robert C, Nyakas M, McArthur GA, Kudchakar R, Mahipal A, Yamada Y, Sullivan RJ, Arance A, Kefford RF, Carlino MS, Hidalgo M, Gomez-Roca C, Michel D, Seroutou A, Aslanis V, Caponigro G, Stuart D, Moutouh-de Parseval L, Demuth T, Dummer R. Clin Cancer Res. 2017. |
| 33. | A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. van Geel RMJM, Tabernero J, Elez E, Bendell JC, Spreafico A, Schuler M, Yoshino T, Delord JP, Yamada Y, Lolkema MP, Faris JE, Eskens FALM, Sharma S, Yaeger R, Lenz HJ, Wainberg ZA, Avsar E, Chatterjee A, Jaeger S, Tan E, Maharry K, Demuth T, Schellens JHM. Cancer Discov. 2017. |
| 34. | Investigations in the possibility of early detection of colorectal cancer by gas chromatography/triple-quadrupole mass spectrometry. Nishiumi S, Kobayashi T, Kawana S, Unno Y, Sakai T, Okamoto K, Yamada Y, Sudo K, Yamaji T, Saito Y, Kanemitsu Y, Okita NT, Saito H, Tsugane S, Azuma T, Ojima N, Yoshida M. Oncotarget. 8(10):17115-17126. 2017. |
| 35. | A phase 1 study of ramucirumab in Japanese patients with advanced solid tumors. Nokihara H, Yamamoto N, Yamada Y, Honda K, Asahina H, Tamura Y, Hozak RR, Gao L, Suzukawa K, Enatsu S, Tamura T. Jpn J Clin Oncol. 47(4):298-305. 2017. |
| 36. | Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study. Saka H, Kitagawa C, Kogure Y, Takahashi Y, Fujikawa K, Sagawa T, Iwasa S, Takahashi N, Fukao T, Tchinou C, Landers D, Yamada Y. Invest New Drugs. 2017. |
| 37. | Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors. Yamamoto N, Nokihara H, Yamada Y, Shibata T, Tamura Y, Seki Y, Honda K, Tanabe Y, Wakui H, Tamura T. Invest New Drugs. 35(2):207-216. 2017. |
| 38. | Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin. Nishikawa K, Yamada Y, Ishido K, Gotoh M, Bando H, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hamada C, Hyodo I. Gastric Cancer. 2016. |
| 39. | Phase I study of the second-generation, recombinant, human EGFR antibody necitumumab in Japanese patients with advanced solid tumors. Tamura Y, Nokihara H, Honda K, Tanabe Y, Asahina H, Yamada Y, Enatsu S, Kurek R, Yamamoto N, Tamura T. Cancer Chemother Pharmacol. 78(5):995-1002. 2016. |
| 40. | A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab. Takahashi N, Iwasa S, Fukahori M, Sudo K, Sasaki Y, Shoji H, Honma Y, Okita NT, Takashima A, Hamaguchi T, Boku N, Shimada Y, Honda K, Yamada T, Yamada Y. Cancer Chemother Pharmacol. 78(3):567-75. 2016. |
| 41. | Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer. Takahashi N, Iwasa S, Sasaki Y, Shoji H, Honma Y, Takashima A, Okita NT, Kato K, Hamaguchi T, Yamada Y. J Cancer Res Clin Oncol. 142(8):1727-38. 2016. |
| 42. | Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients. Tada K, Kitano S, Shoji H, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Yamada Y, Katayama N, Boku N, Heike Y, Hamaguchi T. Cancer Immunol Res. 4(7):592-9. 2016. |
| 43. | Prognostic and predictive value of extended RAS mutation and mismatch repair status in stage III colorectal cancer. Sasaki Y, Akasu T, Saito N, Kojima H, Matsuda K, Nakamori S, Komori K, Amagai K, Yamaguchi T, Ohue M, Nagashima K, Yamada Y. Cancer Sci. 107(7):1006-12. 2016. |
| 44. | Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies. Takahashi N, Iwasa S, Taniguchi H, Sasaki Y, Shoji H, Honma Y, Takashima A, Okita N, Kato K, Hamaguchi T, Shimada Y, Yamada Y. Br J Cancer. 114(9):1003-11. 2016. |
| 45. | Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer. Takahashi N, Furuta K, Taniguchi H, Sasaki Y, Shoji H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Hamaguchi T, Shimada Y, Yamada Y. Oncotarget. 7(4):4925-38. 2016. |
| 46. | Meta-analysis supporting noninferiority of oxaliplatin plus S-1 to cisplatin plus S-1 in first-line treatment of advanced gastric cancer (G-SOX study): indirect comparison with S-1 alone. Hamada C, Yamada Y, Azuma M, Nishikawa K, Gotoh M, Bando H, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hyodo I. Int J Clin Oncol. 21(4):668-75. 2016. |
| 47. | Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors. Nokihara H, Yamada Y, Fujiwara Y, Yamamoto N, Wakui H, Nakamichi S, Kitazono S, Inoue K, Harada A, Taube T, Takeuchi Y, Tamura T. Invest New Drugs. 34(1):66-74. 2016. |
| 48. |
Feasibility of neoadjuvant S-1 and oxaliplatin followed by surgery for resectable advanced gastric adenocarcinoma. Honma Y, Yamada Y, Terazawa T, Takashima A, Iwasa S, Kato K, Hamaguchi T, Shimada Y, Ohashi M, Morita S, Fukagawa T, Machida N, Katai H. |
| 49. |
Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer. |
| 50. |
Discovery of a Good Responder Subtype of Esophageal Squamous Cell Carcinoma with Cytotoxic T-Lymphocyte Signatures Activated by Chemoradiotherapy. Tanaka Y, Aoyagi K, Minashi K, Komatsuzaki R, Komatsu M, Chiwaki F, Tamaoki M, Nishimura T, Takahashi N, Oda I, Tachimori Y, Arao T, Nishio K, Kitano S, Narumi K, Aoki K, Fujii S, Ochiai A, Yoshida T, Muto M, Yamada Y, Sasaki H. |
| 51. | A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors. Nakamichi S, Nokihara H, Yamamoto N, Yamada Y, Honda K, Tamura Y, Wakui H, Sasaki T, Yusa W, Fujino K, Tamura T. Cancer Chemother Pharmacol. 76(6):1153-61. 2015. |
| 52. | Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors. Fujiwara Y, Nokihara H, Yamada Y, Yamamoto N, Sunami K, Utsumi H, Asou H, TakahashI O, Ogasawara K, Gueorguieva I, Tamura T. Cancer Chemother Pharmacol. 76(6):1143-52. 2015. |
| 53. | DNA methylation status as a biomarker of anti-epidermal growth factor receptor treatment for metastatic colorectal cancer. Ouchi K, Takahashi S, Yamada Y, Tsuji S, Tatsuno K, Takahashi H, Takahashi N, Takahashi M, Shimodaira H, Aburatani H, Ishioka C. Cancer Sci. 106(12):1722-9. 2015. |
| 54. | S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies. Iwasa S, Nagashima K, Yamaguchi T, Matsumoto H, Ichikawa Y, Goto A, Yasui H, Kato K, Okita NT, Shimada Y, Yamada Y. Cancer Chemother Pharmacol. 76(3):605-14. 2015. |
| 55. | Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutations (JO25567): an open-label, randomized, multicenter, phase II study. Yoshida K, Yamada Y. Transl Lung Cancer Res. 4(3):217-9. 2015. |
| 56. | Current Status of Single-Agent Phase I Trials in Japan: Toward Globalization. Mizugaki H, Yamamoto N, Fujiwara Y, Nokihara H, Yamada Y, Tamura T. J Clin Oncol. 33(18):2051-61. 2015. |
| 57. | A phase I study of resminostat in Japanese patients with advanced solid tumors. Kitazono S, Fujiwara Y, Nakamichi S, Mizugaki H, Nokihara H, Yamamoto N, Yamada Y, Inukai E, Nakamura O, Tamura T. Cancer Chemother Pharmacol. 75(6):1155-61. 2015. |
| 58. | Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors. Nakamichi S, Nokihara H, Yamamoto N, Yamada Y, Fujiwara Y, Tamura Y, Wakui H, Honda K, Mizugaki H, Kitazono S, Tanabe Y, Asahina H, Yamazaki N, Suzuki S, Matsuoka M, Ogita Y, Tamura T. Invest New Drugs. 33(3):641-51. 2015. |
| 59. | Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer. Nishio M, Horiike A, Nokihara H, Horinouchi H, Nakamichi S, Wakui H, Ohyanagi F, Kudo K, Yanagitani N, Takahashi S, Kuboki Y, Yamamoto N, Yamada Y, Abe M, Tahata T, Tamura T. Invest New Drugs. 33(3):632-40. 2015. |
| 60. | Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer. Takahashi N, Yamada Y, Furuta K, Nagashima K, Kubo A, Sasaki Y, Shoji H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Hamaguchi T, Shimada Y. Cancer Sci. 106(5):604-10. 2015. |
| 61. | Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hamada C, Hyodo I. Ann Oncol. 26:141-148, 2015. |
|
2014 - 2001 |
|
| 62. | A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study). Hamamoto Y, Yamaguchi T, Nishina T, Yamazaki K, Ura T, Nakajima T, Goto A, Shimada K, Nakayama N, Sakamoto J, Morita S, Yamada Y. Oncologist. 19(11):1131-2. 2014. |
| 63. | Leucovorin, fluorouracul, and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Yamada Y, Takahari D, Matsumoto H, Baba H, Nakamura M, Yoshida K, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, Sasaki Y, Satoh T, Takahashi K, Mishima H, Muro K, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K. Lancet Oncol. 14:1278-1286, 2013. |
| 64. | Adipocytokines as new promising markers of colorectal tumors: Adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Nakajima TE, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S, Kato K, Hamaguchi T, Shimada Y. Cancer Sci. 101:1286-1291, 2010. |
| 65. | PhaseI/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer. Yamada Y, Tahara M, Miya T, Satoh T, Shirao K, Shimada Y, Ohtsu A, Sasaki Y, Tanigawa Y. Br J Cancer. 98：1034-1038,2008. |
| 66. | Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples. Yamada Y, Arao T, Gotoda T, Taniguchi H, Oda I, Shirao K, Shimada Y, Hamaguchi T, Kato K, Hamano T, Koizumi F, Tamura T, Saito D, Shimoda T, Saka M, Fukagawa T, Katai H, Sano T, Sasako M, Nishio K. Cancer Sci. 99:2193-2199, 2008. |
| 67. | Impact of insulin-like growth factor type 1receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Matsubara J, Yamada Y, Hirashima Y, Takahari D, Okita NT, Kato K, Hamaguchi T, Shirao K, Shimada Y, Shimoda T. Clin Cancer Res. 14:3022-3029, 2008. |
| 68. | Impacts of excision repair cross-complementing gene I (ERCCI), dihydroprimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Matsubara J, Nishina T, Yamada Y, Iwaki T, Shimoda T, Kajiwara T, Nakajima TE, Kato K, Hamaguchi T, Shimada Y, Okayama Y, Oka T, Shirao K. Br J Cancer. 98:832-839, 2008. |
| 69. | Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Goto A, Yamada Y, Shirao K, Shimada Y, Muro K, Hamaguchi T, Yasui H, Kato K. Ann Oncol. 17: 968-973, 2006. |
| 70. | Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. Yamada Y, Hamaguchi T, Goto M, Muro K, Matsumura Y, Shimada Y, Shirao K, Nagayama S. Br J Cancer. 89: 816-820, 2003. |
| 71. | Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, Miyata Y and Taguchi T. Ann Oncol. 12: 1133-1137, 2001. |
講師 柄山 正人
| 1. | Respiratory impedance is correlated with morphological changes in the lungs on three-dimensional CT in patients with COPD. Karayama M, Inui N, Mori K, Kono M, Hozumi H, Suzuki Y, Furuhashi K, Hashimoto D, Enomoto N, Fujisawa T, Nakamura Y, Watanabe H, Suda T. Sci Rep. 7:41709, 2017. |
| 2. | Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease. Enomoto Y, Suzuki Y, Hozumi H, Mori K, Kono M, Karayama M, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Suzuki D, Ogawa N, Nakashima R, Mimori T, Iwashita T, Suda T. Arthritis Res Ther. 19(1):9, 2017. |
| 3. | Utility of Macrophage Activated Marker, CD163, for Diagnosis and Prognosis in Pulmonary Tuberculosis. Suzuki Y, Shirai M, Asada K, Miwa S, Karayama M, Nakamura Y, Inui N, Shirai T, Hayakawa H, Baba S, Suda T. Ann Am Thorac Soc. 14(1):57-64, 2017. |
| 4. | Continuation maintenance therapy with S-1 in chemotherapy-naive patients with advanced squamous cell lung cancer. Suzuki S, Karayama M, Inui N, Fujisawa T, Enomoto N, Nakamura Y, Kuroishi S, Matsuda H, Yokomura K, Koshimizu N, Toyoshima M, Imokawa S, Asada K, Masuda M, Yamada T, Watanabe H, Suda T. Invest New Drugs. 34(4):490-6, 2016. |
| 5. | Sequential addition of aprepitant in patients receiving carboplatin-based chemotherapy. Suzuki S, Karayama M, Inui N, Kuroishi S, Fujisawa T, Enomoto N, Nakamura Y, Yokomura K, Toyoshima M, Imokawa S, Asada K, Masuda M, Yamada T, Watanabe H, Hayakawa H, Suda T. Med Oncol. 33(7):65,2016. |
| 6. | Increased levels of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in idiopathic pulmonary fibrosis. Kono M, Nakamura Y, Oyama Y, Mori K, Hozumi H, Karayama M, Hashimoto D, Enomoto N, Fujisawa T, Inui N, Yamada M, Hamada E, Colby TV, Maekawa M, Suda T. Respir Med. 115:46-52,2016. |
| 7. | Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer. Enomoto Y, Inui N, Kato T, Baba T, Karayama M, Nakamura Y, Ogura T, Suda T. Lung Cancer 96:63-67, 2016. |
| 8. | Changes in cross-sectional area of pulmonary vessels on chest computed tomography after chemotherapy in patients with advanced non-squamous non-small-cell lung cancer. Karayama M, Inui N, Kusagaya H, Suzuki S, Inoue Y, Enomoto N, Fujisawa T, Nakamura Y, Suda T. Cancer Chemother Pharmacol. 77(5):1011-8, 2016. |
| 9. | Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. Karayama M, Inui N, Fujisawa T, Enomoto N, Nakamura Y, Kuroishi S, Yokomura K, Koshimizu K, Sato M, Toyoshima M, Shirai T, Masuda M, Yamada T, Imokawa S, SudaT. Eur J Cancer 58:30-37,2016. |
| 10. | Clinicopathological and Survival Analysis of Japanese Patients with Resected Non-Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1, or PIK3CA Gene Amplification. Inoue Y, Matsuura S, Kurabe N, Kahyo T, Mori H, Kawase A, Karayama M, Inui N, Funai K, Shinmura K, Suda T, Sugimura H. J Thorac Oncol 10(11): 1590-600, 2015. and more. karayama gyouseki.docx |